- Technology Management
- For Industry - Technology Available for Licensing
- Contact Technology Management
- old pages
- A Modern Approach to Wing Warp for Aircraft Control
- Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
- Compositions and Methods for Treating and Diagnosing Hepatoma
- Vaccine Compositions and Methods That Increase Safety of Anti-Viral Vaccination Without Loss of Efficacy
- Automatic Pressure-Locking Valve Prevents CSF Loss and Herniation During Lumbar Puncture When Intracranial Pressure Is Elevated.
- Immortal Differentiated Type II Lung Epithelial Cell Line (T7)
- Human A Rapid, Reliable Bedside Diagnostic Method For Accurately Determining Feeding Tube Placement In Respiratory Tract, Stomach, Or Small Bowel Of Patients Prior to Enteral Nutrient Administration.
- Human Natural Killer Cell Line - NK 3.3:
- Factor IXa Protease Helix-330 (Region 1)
- In Vitro Method for Concerted Integration of Donor DNA Molecules Into Target DNA Using Retroviral Integrase and a Procedure for Evaluation of Donor DNA Integration.
- SRCAP: A Novel Transcription Protein Having Therapeutic Target and Diagnostic Target Product Development Potential.
- C-Terminal Binding Protein Interacting Protein (CtIP):
- Novel Anti-Coagulation Therapeutics: Agents That Effectively Inhibit Binding of Factor VIIIa (Region 3) With Factor IXa (Region 2) Without Activating Factor X.
- Genetically Modified Activated Protein C with Reduced Anticoagulant Properties
- C22: A Conditionally Immortalized Mouse Clara Cell Line
SRCAP: A Novel Transcription Protein Having Therapeutic Target and Diagnostic Target Product Development Potential.
Inventor: Dr. John C. Chrivia and Dr. Peter Yaciuk
Transcription factors are proteins which bind to regulatory regions of genes and other proteins and thereby modulate the transcription of genes. The action of transcription factors is affected by co-activators, most notably by the CREB binding protein (CBP). CBP is an acetyltransferase capable of acetylating histones and various transcription factors such as GATA-1 and p53. A novel transcriptional co-activator for CBP, designated as SRCAP, has been identified. SRCAP is a Snf2 family member. As such it has ATPase activity. SRCAP is also capable of activating gene transcription without CBP. SRCAP is capable of interacting with CBP, DEAD box helicases, adenoviral DBP protein, ß-actin, DNA and nuclear receptors.
Available human SRCAP-related reagents include SRCAP protein, SRCAP cDNA, nucleotides, peptides, SRCAP chimera (GAL4), DNA and RNA antisense oligonucleotides, ribozymes, vectors, and monoclonal antibodies. SRCAP and the SRCAP-related reagents have utility for (i) development of diagnostic tests designed to assess SRCAP activity in biological and clinical test samples, and, (ii) SRCAP could be a therapeutic target for treatment of diseases that involve inappropriate transcriptional activation modulated by SRCAP or CBP including viral infections, cancer, and central nervous system disorders.
Keywords: HTLV-1, SNF2/SW12, c-jun, c-myb, MyoD, E2F1, YY1, TBP, TFIIB, RNAP II, adenoviral DBP protein, nuclear receptors
Patent: U.S. Patent No. 6,365,372
License: Collaborative research and licensing opportunities are available.
Reference Number: SLU 99-009